gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain Injuries
Study Findings: New research presented at the 2025 International Brain Injury Association World Congress shows that gammaCore® non-invasive vagus nerve stimulation (nVNS) significantly alleviates concussive symptoms in patients with mild traumatic brain injury (mTBI), demonstrating improvements in headaches, nausea, dizziness, and depression.
Company Overview: electroCore, Inc. is a bioelectronic medicine company focused on commercializing nVNS technology for treating medical conditions and promoting wellness, emphasizing the potential of neuromodulation as a treatment option for mTBI symptoms.
Trade with 70% Backtested Accuracy
Analyst Views on ECOR
About ECOR
About the author

- Leadership Transition: electroCore CEO Daniel Goldberger announced his retirement effective April 1, 2026, marking a pivotal shift in the company's financial and commercial strategy, with CFO Joshua Lev appointed as Interim President to ensure stability during the leadership transition.
- Strong Financial Performance: The company reported fourth-quarter 2025 revenue of $9.2 million, a 31% year-over-year increase, with full-year revenue reaching $32 million, a 27% growth over 2024, indicating sustained market demand for non-invasive pain therapeutics.
- Optimistic Outlook: Management expects revenue for 2026 to continue growing at approximately 30%, although detailed guidance is not provided due to the leadership transition; however, third-quarter activities suggest ongoing product acceptance in the market.
- Product Expansion Plans: The company plans to launch Quell Relief for lower extremity pain in 2026 and is developing next-generation mobile applications for both Truvaga and Quell, aiming to further expand the applications of its non-invasive neuromodulation platform.
- Revenue Guidance: electroCore anticipates 2025 revenue between $31.8M and $32M, slightly below the consensus of $31.81M, indicating a cautious outlook on future growth.
- Q4 Growth Projection: The company expects Q4 2025 revenue to be between $9M and $9.2M, representing approximately 30% growth over Q4 2024, suggesting strengthening competitive positioning in the market.
- Cash Position: By the end of 2025, electroCore expects to have approximately $11.6M in cash, down from about $13.2M as of September 30, 2025, reflecting pressure from expansion and investment expenditures.
- Market Reaction: ECOR shares fell 0.62% in premarket trading to $7.0957, indicating investor caution regarding the revenue outlook.

Management Strategy: Dr. Thomas Errico highlighted a strategic shift towards growth through targeted investments, acquisitions, and partnerships, focusing on expanding product offerings and enhancing shareholder value while deferring profitability.
Financial Performance: The company reported a record revenue of $8.7 million for Q3 2025, a 33% increase year-over-year, with strong gross margins of 86%, driven by prescription device sales and growth in the VA hospital system.
Outlook and Guidance: CEO Daniel Goldberger raised the full-year revenue guidance to $31.5 million to $32.5 million, projecting a cash balance of approximately $10.5 million by year-end and aiming for positive adjusted EBITDA in the second half of 2026.
Risks and Challenges: Management acknowledged ongoing litigation and the impact of macroeconomic factors on revenue, emphasizing that continued investments in sales and R&D may delay near-term profitability but are essential for long-term growth.

electroCore Stock Offering: electroCore has filed to sell 762,508 shares of common stock for existing holders, with the prospectus clarifying that it is not an offer to sell these securities.
Market Updates: Other companies mentioned include NVDX with a leveraged growth strategy, ISM Services indicating a potential recession, Energy Transfer offering a 7.80% yield, Apollo Silver increasing its private placement, and Uranium Energy pricing a public offering of 15.5 million shares.

Virtual Investor Conference Overview: The Metals and Mining Virtual Investor Conference took place from May 6th to 8th, 2025, with presentations now available for online viewing for 90 days. Investors can access materials and request one-on-one meetings until May 13th.
Participating Companies: Notable companies presenting include Northern Superior Resources Inc., Canada Nickel Company Inc., and Novo Resources Corp., among others, showcasing a range of investment opportunities in the metals and mining sector.







